BIVI

Biovie Inc

1.640

-0.630-27.75%

After Hours: 1.650 +0.010 +0.61%19:56 07/13 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE2.230/2.270

TODAY RANGE1.580-2.250

VOL688.93K

MARKET CAP12.37M

52 WEEK RANGE1.060-9.09

AVG VOL (3M)144.84K

% TURNOVER9.13%

TURNOVER--

P/E (TTM)-0.3791

% RANGE29.07%

EPS(TTM)-4.3264

P/E(FORWARD)-0.5559

P/B0.7925

BVPS2.070

DIVIDEND--

P/S--

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP12.32M

SHARES OUTSTANDING7.54M

NEXT EARNINGS08/13-08/17

FREE FLOAT7.51M

LOT SIZE1

EX-DATE07/07/2025

News

Press Releases

Financial Reports

Profile

TipRanks·06/18 21:25
BioVie files $300M mixed securities shelf
Reuters·06/18 21:22
BIOVIE - FILES TO OFFER UP TO $300 MLN IN SECURITIES - SEC FILING
PUBT·06/02 14:20
BioVie posts corporate presentation spotlighting bezisterim longevity-focused therapy pipeline
PUBT·05/27 12:03
BioVie to host live investor webinar with CEO presentation and Q&A
NASDAQ·05/26 15:27
BioVie Completes Enrolment In Phase 2 ADDRESS-LC Trial For Bezisterim In Treating Long COVID
TipRanks·05/26 12:32
BioVie announces full enrollment of ADDRESS-LC trial of bezisterim
PUBT·05/26 12:06
BioVie completes enrollment in Phase 2 long COVID trial of bezisterim, targets late summer 2026 data
Reuters·05/26 12:00
BIOVIE ANNOUNCES FULL ENROLLMENT OF THE ADDRESS-LC TRIAL OF BEZISTERIM FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LONG COVID
TipRanks·05/18 12:08
BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease
PUBT·05/18 12:04
BioVie completes Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson’s disease
Reuters·05/18 12:00
BIOVIE ANNOUNCES COMPLETION OF PHASE 2 SUNRISE-PD TRIAL IN EARLY-STAGE PARKINSON’S DISEASE
PUBT·05/11 20:57
BioVie Q3 FY26 net loss widens to $5.3 million; operating expenses climb to $5.4 million
PUBT·04/14 12:05
BioVie SUNRISE-PD bezisterim abstract accepted for presentation at 2026 AAN meeting
Reuters·04/01 22:27
BioVie publishes corporate presentation on bezisterim pipeline catalysts in Parkinson’s, Long Covid
Reuters·03/12 12:05
BioVie to present SUNRISE-PD bezisterim poster at AD/PD 2026

Same Industry

Name/Symbol

Change%

Price

BIVI

Regeneron Pharmaceuticals

REGN

+2.06%

632.90

GridAI Tech

GRDX

-1.14%

4.350

BIONTECH

BNTX

+3.47%

97.18

United Therapeutics Corp.

UTHR

-0.57%

541.83

Siga Technologie

SIGA

-0.76%

3.920

Vertex Pharmaceuticals Inc

VRTX

+0.29%

529.59

Moderna

MRNA

+12.59%

67.27

Charles Riv Labs Intl Inc

CRL

+0.09%

229.30

Medpace Holdings

MEDP

+1.37%

527.07

Talphera Inc

TLPH

+7.35%

1.460

ICON plc

ICLR

+0.42%

173.71

CBPO

Iqvia Hldgs Inc

IQV

+5.17%

203.20

MOLECULAR PARTNERS AG

MOLN

+0.50%

4.000

Arcturus Therape

ARCT

+0.96%

7.35

Gilead Sciences Inc

GILD

+3.68%

130.61

PRA Health

PRAH

0.00%

165.21

Aptevo Therapeutics Inc

APVO

-0.66%

4.550

INCY

Biospecifics

BSTC

0.00%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.